Skip to content
Screener

Edwards Lifesciences EW Restricted Cash

Restricted Cash at other companies

Boston Scientific logo
Boston ScientificBSX
$71M-31.1%

Other financials

Income statement

See full
Revenue$1.7B+13.6%
Gross profit$1.3B+13.5%
Operating income$513.2M+24.8%
Net income$241.9M-27.4%
EPS (diluted)$0.42-25.0%

Balance sheet

See full
Cash & equivalents$2.4B-22.3%
Total debt$702.9M+0.5%
Total equity$10.3B+2.0%
Total assets$13.3B+2.3%

Cash flow

See full
Operating cash flow$43.8M-84.4%
CapEx$64.9M+15.9%
Free cash flow-$21.1M-109%

Valuation

See full
Market cap$51.28B+11.2%
Enterprise value$49.54B+11.0%
P/E51×+39.9×
P/S7.9×-0.2×

Profitability

See full
Gross margin77.8%-1.0pp
Operating margin22.3%-3.6pp
Net margin15.4%-57.5pp
FCF margin17.3%—

Returns & leverage

See full
Return on equity10.7%-37.8pp
Debt / equity0.1×0.0×
Current ratio4.4×0.0×

Where this comes from

Reported directly by Edwards Lifesciences in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashCurrent.

The source filing: Edwards Lifesciences’s 10-Q, filed May 6, 2026. Open the filing →

Filed
May 6, 2026, 4:12 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001099800-26-000026

FAQ

What is Edwards Lifesciences's restricted cash?
Edwards Lifesciences (EW) reported restricted cash of $1M in Q1 2026.
What is the long-term trend for Edwards Lifesciences's restricted cash?
Over 4 years (2020 to 2025), Edwards Lifesciences's restricted cash has grown at a -58.3% compound annual growth rate (CAGR), from $16.6M to $500K.
What does restricted cash mean?
Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.

Ask your AI about Edwards Lifesciences's restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude